Neurotrophic Composition for Cerebral Palsy Language Development
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nutritional interventions have not adequately studied the impact of increased nutritional intake in the first years of life on neurodevelopmental outcomes in children with cerebral palsy, and there is a need to investigate dietetic and nutritional interventions for improving language skills in children at risk of neurological impairments.
Innovation Solution
A composition comprising uridine monophosphate (UMP), docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), and choline, administered in specific ranges per kcal or ml, is used to improve language skills and reduce language skills impairment in children with suspected or confirmed cerebral palsy, as measured by the Bayley III scales.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If increased nutritional intake is provided in the first years of life for children with cerebral palsy, then growth and neurodevelopmental outcomes may be improved, but the impact has not been adequately studied and evidence is insufficient
Solution Approach 1:
The patent applies preliminary action by administering neurotrophic factors (uridine, choline, DHA, EPA) to children with cerebral palsy during the critical early years of life, before significant neurodevelopmental deficits are established. This preventive approach aims to support brain development and prevent further impairment rather than treating established conditions.
Solution Approach 2:
The patent employs parameter changes by systematically varying the dosage and composition of neurotrophic factors in the nutritional intervention. Different combinations and concentrations of uridine, choline, DHA, and EPA are tested to determine optimal dosing parameters that maximize neurodevelopmental benefits while ensuring safety.
2Reliability
If dietetic and nutritional intervention is implemented to improve language skills in children at risk of neurological impairments, then language development may be enhanced, but the specific composition and dosage ranges need to be precisely defined
Solution Approach 1:
The patent applies parameter changes by establishing specific dosage ranges for each neurotrophic factor: uridine (10-200 mg per 100 kcal), choline (60-350 mg per 100 kcal), DHA (250-9000 mg per 100 kcal), and EPA (250-9000 mg per 100 kcal). These precise parameter definitions enable standardized formulation of the nutritional intervention.
Solution Approach 2:
The patent uses composite materials by combining multiple neurotrophic factors (uridine, choline, DHA, EPA) into a single formulated composition. This composite approach allows the synergistic interaction of different substances to work together, enhancing language development more effectively than individual components alone.
3Reliability
If a composition with specific neurotrophic factors is administered to children with cerebral palsy, then language skills improve, but the composition must be carefully formulated to ensure safety and effectiveness
Solution Approach 1:
The patent applies parameter changes by defining specific concentration ranges for each ingredient in the composition formulation. The standardized parameters (uridine: 10-200 mg/100 kcal, choline: 60-350 mg/100 kcal, DHA: 250-9000 mg/100 kcal, EPA: 250-9000 mg/100 kcal) simplify the complex task of formulation while ensuring both safety and effectiveness.
Solution Approach 2:
The patent applies local quality by tailoring the composition formulation to the specific needs of children with cerebral palsy, focusing on the particular neurodevelopmental deficits they experience. The formulation is optimized for the specific population rather than using a generic approach, addressing the unique requirements of this patient group.
Data Source
AI summary
The invention pertains to the use of therapeutically effective amounts of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, (ii) docosahexaenoic acid (22:6; DHA), and/or eicosapentaenoic acid (20:5; EPA), or esters thereof, and (iii) choline, or salts or esters thereof, in the manufacture of a product for therapeutically improving language development and reducing language skills impairment in children with suspected or confirmed cerebral palsy, or children at risk thereof.